StockNews.com Begins Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

Equities researchers at StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a note issued to investors on Saturday. The firm set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets decreased their target price on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a research note on Monday, November 11th.

NovaBay Pharmaceuticals Price Performance

Shares of NBY stock opened at $0.62 on Friday. The business has a 50-day moving average of $0.63 and a 200 day moving average of $0.88. NovaBay Pharmaceuticals has a 1-year low of $0.36 and a 1-year high of $9.08. The stock has a market capitalization of $3.03 million, a PE ratio of -0.01 and a beta of 0.65.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.